GEN Exclusives

More »

GEN News Highlights

More »
Sep 6, 2007

Aradigm and CyDex Combine Expertise to Tackle Asthma and COPD

  • Aradigm and CyDex are collaborating to combine products for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).

    “Putting together Cydex’ aqueous formulation capabilities with Aradigm’s palm-size AERx Essence inhalation delivery system has the potential to generate a family of attractive novel therapies for asthma and COPD patients,” John Siebert, CEO of CyDex said.

    Under the two-year agreement, Aradigm will bear 60% of the costs of development, and CyDex will be responsible for the rest. Third-party licensing and sales revenues will be shared in the same ratio.

    The companies will develop and commercialize products containing inhaled corticosteroids, anticholinergics, and beta-2 agonists.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?